MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (June 2016)

30 slides from MabVax Therapeutics's investor presentation, Jun 15, 2016

  1. Slide 1: Immuno-Oncology Products Discovered From The Human Immune Response to Cancer

    Slide 1: Immuno-Oncology Products Discovered From The Human Immune Response to Cancer

    M M abVax a therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer David Hansen President and CEO June 2016 Corporate Presentation ——S

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER Forward Looking Statements ‘This contains forward-looking statements and projections. ‘The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and completene

  3. Slide 3: Key Highlights

    Slide 3: Key Highlights

    KEY HIGHLIGHTS « HuMab Discovery Platform: antibody-based products derived from the human immune response to cancer — Developed platform for antibody discovery resulting in portfolio of fully human antibodies = Integrated approach to pment of cancer di along with thera Initial target is For pancreat

  4. Slide 4: MabVax Discovery Platform: Therapies Derived From The Natural Human Immune Response

    Slide 4: MabVax Discovery Platform: Therapies Derived From The Natural Human Immune Response

    MABVAX DISCOVERY PLATFORM: THERAPIES DERIVED FROM THE NATURAL HUMAN IMMUNE RESPONSE | | hoc] => Focused Discovery Screening Optimized Therapy * Vaccination drives specific * Highly efficient screening + Fully human antibodies have against pre-identified targets rget * Survey response across multiple

  5. Slide 5: HuMab-5B1 Demonstrates Integrated Antibody Clinical Development Platform

    Slide 5: HuMab-5B1 Demonstrates Integrated Antibody Clinical Development Platform

    HUMAB-5B1 DEMONSTRATES INTEGRATED ANTIBODY CLINICAL DEVELOPMENT PLATFORM ‘Therapeutic Antibody (MVT-5873) 7 , tolerability as single agent ted February 2016 with early read on trial 3Q16 * Clinical Trials. gov Identifier: NCT02672917 * Clear all dosage levels for follow-on products l> Immuno-PET Ima

  6. Slide 6: MabVax Has Rich Pipeline of Product Candidates

    Slide 6: MabVax Has Rich Pipeline of Product Candidates

    MABVAX Has RICH PIPELINE OF PRODUCT CANDIDATES Program Indication Collaborators 5); Pre-IND Phase1 Phase 2 iscovery ‘Commercial Rights rans MEINE PEN KG wvrses Os we ole i eee GI Cancers ww PET-Imaging SCRI, Patheon Metastatic Pancreatic MVr.1075 . Radioimmanotherapy “" KC > on Metastatic Pancreatic

  7. Slide 7: Lead Antibody Program — HuMab-5B1

    Slide 7: Lead Antibody Program — HuMab-5B1

    LEAD ANTIBODY PROGRAM — HUMAB-5B1 SLEA ANTIGEN EXPRESSED ON MULTIPLE SOLID TUMOR CANCERS a or HuMab-5B1 derived from a patient vaccinated . with MabVax vaccine licensed from MSKCC ii i * Patients repeatedly vaccinated to drive immune Senin response against cancer antigen 3 — 7 sin (a) « Patient samp

  8. Slide 8: Sialyl Lewis A as a Target for Cancer Therapeutics

    Slide 8: Sialyl Lewis A as a Target for Cancer Therapeutics

    SIALYL LEWIS AS A TARGET FOR CANCER THERAPEUTICS + ° PS Sialyl Lewis A antigen (CA19-9) is the most frequently utilized and only validated serum marker for assessment of pancreatic cancers Expression of sLe* facilitates tumor Sia! Lewist eh proliferation, invasion, and metastatic spread! High copy n

  9. Slide 9: HuMab-5B1 Has Ideal Characteristics That Enable Development of Product Platform

    Slide 9: HuMab-5B1 Has Ideal Characteristics That Enable Development of Product Platform

    HUMAB-5B1 Has IDEAL CHARACTERISTICS THAT ENABLE DEVELOPMENT OF PRODUCT PLATFORM Character Technical Advantage of HuMal Description “Targeting cancer cell Specificity Exquisitely specific; only recognizes the target on cancer cell Binds tightly to target. Affinity Binds quickly to cancer cell and is

  10. Slide 10: HuMab-5B1 Specificity

    Slide 10: HuMab-5B1 Specificity

    HUMaB-5B1 SPECIFICITY HIGHLY SPECIFIC TO sLEA ANTIGEN BY GLYCAN ARRAY ANALYSIS Exquisite binding to Sialyl Lewis A structural antigens from a database of 462 antigens! 581 (10ug/mL) Slkde# 12987 CFGH# 2008 06/25/2010 V4.1 Aloxad@8 CMZ 445000 40000 NeuSAca2-3Galf1-3(Fuca1-4)GIcNAcB, 35000 (Neu5Ac-Le?

  11. Slide 11: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    Slide 11: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers

    HUMaAsB-5Bi ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer . Pancreatic ductal adenocarcinoma B. Colon carcinoma . Lung adenocarcinoma . Urinary bladder, mucinous adenocarcinoma ‘. Colon metastatic to ovary ©, Breast car

  12. Slide 12: MVT-5873 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    Slide 12: MVT-5873 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    MVT-5873 DEMONSTRATES SUBSTANTIAL POTENTIATION OF ANTI- TUMOR E! [ OF SOC CHEMOTHERAPY IN PANCREATIC CANCER L:fficacy evaluated as for advanced or met single agent and in combination with standard of care chemotherapy static PDAC Dose-dependent inhibition of tumor growth observed with single-agent M

  13. Slide 13: HuMab-5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    Slide 13: HuMab-5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy

    HUMAB-5B1 DEMONSTRATES SUBSTANTIAL POTENTIATION OF ANTI- ‘TUMOR EFFECT OF SOC CHEMOTHERAPY IN PANCREATIC CANCER Relative Tumor Growth at Day 42 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Xenograft Model = 3 é = 8 2 2 2 i 6 soc SOC Plus SOC Plus SOC Plus Control MVT-5873 MVT-5873 MVT-5873 [5 mg/kg]

  14. Slide 14: HuMab-5B1 Demonstrates Substantial Anti-Tumor Effect in Small Cell Lung Cancer Model

    Slide 14: HuMab-5B1 Demonstrates Substantial Anti-Tumor Effect in Small Cell Lung Cancer Model

    HUMAB-5B1 DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN SMALL CELL LUNG CANCER MODEL oa ae Potentiation of Tumor Growth Inhibition and Growth Delay Seen When Combined With Chemotherapy 2500 P= Hu IgG 50mg/kg (control) SP MVT-5873 25 mg/kg - 2000 —S—MVT-5873 50 mg/kg — Paclitaxel 10 me/kg ¢ 1500 “~®—

  15. Slide 15: MVT-2163 HuMab Immuno-PET Imaging Agent

    Slide 15: MVT-2163 HuMab Immuno-PET Imaging Agent

    MVT-2163 HUMAB IMMUNO-PET IMAGING AGENT ¢ Significant unmet medical need for improved diagnosis and monitoring of pancreatic cancer Preclinical data demonstrate potential for new HuMab-5Bibased PET agent Radiolabel abundant, commercially available, relatively inexpensive, & readily amenable to conju

  16. Slide 16: MVT-2163 Improves Imaging Compared to Standard Agent in Use Today

    Slide 16: MVT-2163 Improves Imaging Compared to Standard Agent in Use Today

    MVT-2163 IMPROVES IMAGING COMPARED TO STANDARD AGENT IN USE TODAY Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts — The co-nghntion of FOGPET end computed Acq "Ze rioibed SB antibody (72301) soma (te) an pn eos of PET nage of te ee mone co-egitered ih icine FOG-PET only (

  17. Slide 17: Dual Labeled HuMab-5B1 May Provide Insights During Surgical Resection

    Slide 17: Dual Labeled HuMab-5B1 May Provide Insights During Surgical Resection

    DUAL LABELED HUMAB-5B1 MAy PROVIDE INSIGHTS DURING SURGICAL RESECTION ——— — Dual labeled HuMab-5B1 (Zr & NIRP) retains targeting ability * Suite-2 tumors and metastases visualized by P and UV light surgical guidance for tamor resection can become feasible Inti J. Houghton, Site-specifically labeled

  18. Slide 18: MVT-1075 HuMab-5B1 Radioimmunotherapy (RIT)

    Slide 18: MVT-1075 HuMab-5B1 Radioimmunotherapy (RIT)

    MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY (RIT) ¢ Combines established efficacy of radiation therapy with tumor specific targeting ¢ Product has potential to deliver more potent HuMab-5B1 based product @ 'Lu isa low-energy comm emitter with a relatively short tissue penetration range 1.6 mm) p i inimizi

  19. Slide 19: MVT-1075 Radioimmunotherapy Demonstrates Substantial Tumor Growth Suppression and Regression

    Slide 19: MVT-1075 Radioimmunotherapy Demonstrates Substantial Tumor Growth Suppression and Regression

    MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY DEMONSTRATES SUBSTANTIAL ‘TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION * 377Lu-CHX-A"-DTPA-5B1 iodistribution of 177 Lu-CHX-A”-DTPA-5B1 N=8 for all groups Normalized Tumor Volume CPG ISA PAP? Time (days) + niin erent tom Conta (PBS) ou Preferential tumor target

  20. Slide 20: MVT-1075 Radioimmunotherapy: Orthotopic PDAC Model Demonstrates Tumor Regression

    Slide 20: MVT-1075 Radioimmunotherapy: Orthotopic PDAC Model Demonstrates Tumor Regression

    MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION Post-1 Tumor Growth -e Control (saline) -» *7Lu-5B1 (300 iCi) Tumor Volume (mm?) C) 5 10 15 20 25 Time after RIT Administration (days) All work done in collaboration with and in the lab of Jason S, Lewis, Ph.D.

  21. Slide 21: HuMab-5B1 Based Antibody Drug Conjugate (ADC)

    Slide 21: HuMab-5B1 Based Antibody Drug Conjugate (ADC)

    HUMAB-5B1 BASED ANTIBODY DRUG CONJUGATE (ADC) « HuMab-5B1 has ideal characteristics for ADC 4 Antibody is readily internalized ¢ Large number of targets on cach cll ° Proof of concept already demonstrated « Multiple linker/toxin combinations are being evaluated to identify the best ADC candidate to

  22. Slide 22: HuMab-5B1 ADC Demonstrates Significant Efficacy in Multiple Tumor Cell Lines

    Slide 22: HuMab-5B1 ADC Demonstrates Significant Efficacy in Multiple Tumor Cell Lines

    HuMas-5B1 ANTIBODY DRUG CONJUGATE DEMONSTRATES SIGNIFICANT EFFICACY IN MULTIPLE TUMOR CELL LINES pangs gyre ung capes - F : ‘ 4 Matt , i smomoonn el itp + reoesoouaiey : : wg im oo ; be i> Internalization of HuMab-5B1 s 2 Into BxPC3 Pancreatic Cancer Cells Ses - conan Pa 2: co sai as : " ay “| = ‘ma

  23. Slide 23: HuMab-5B1 ADC In Vivo Linker Optimization Study Demonstrates Efficacy

    Slide 23: HuMab-5B1 ADC In Vivo Linker Optimization Study Demonstrates Efficacy

    HUMAB-5B1 ANTIBODY DRUG CONJUGATE IN VIVO LINKER OPTIMIZATION STUDY DEMONSTRATES EFFICACY 600.00 500.00 + 00 + Mean Tumor Volume P—Group 01: PBS (10mi/kg) * SBI-ADC shows dose dependent a croupon:husetaocs (ame) tumor growth ion and regression at se-croup ot: hus A0C8 (ame) higher do: o6roup 05: hus

  24. Slide 24: HuMab-5B1 ADC Tolerability Demonstrated Across Escalating Toxin Doses

    Slide 24: HuMab-5B1 ADC Tolerability Demonstrated Across Escalating Toxin Doses

    HuUMasB-5B1 ANTIBODY DRUG CONJUGATE TOLERABILITY DEMONSTRATED ACROSS ESCALATING TOXIN DOSES _ — 10 pit PBS 18 2 in TARR 300 3 ug/kg, 5 © oe g10p3 > PBS 8 100 t% Aan 150 H ugg re soe gro PBS 85 80 - Ein 0 3 6 9 1215 SC«MOg/Ag Days after treatment * Measure weight loss to determine toxicity * Weight l

  25. Slide 25: Key Milestones for HuMab-5B1 Development Program for 2016 and 2017

    Slide 25: Key Milestones for HuMab-5B1 Development Program for 2016 and 2017

    Key MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAM FOR 2016 AND 2017 HuMab-5B1 ADC Next HuMab Development Candidate M Mabyax Earlyreadouton + Complete enrollment escalation safety safety and PK read out on Phase I Trial + Initiate combo with combo with chemo chemo study trial + Initiate dose + Early re

  26. Slide 26: Robust Intellectual Property

    Slide 26: Robust Intellectual Property

    ROBUST INTELLECTUAL PROPERTY 4 11issued patents and 3 pending applications in the US. Issued patents covering monovalent and polyvalent vaccines, methods of manufacture, methods of use 2 pending applications covering monoclonal antibodies 4 14 international patents and 3 pending applications — Issue

  27. Slide 27: Strong Management Team and Board of Directors

    Slide 27: Strong Management Team and Board of Directors

    STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen Founder, President && CEO ard Member Philip Livingston, M.D. Founder & Chief Science Oicer Gregory Hanson vit ent Bienes ‘Schering-Plough, Key ‘Memorial oan Kenesing Center Avani Fist Comers Wolfgang Scholz, Ph.D. Founder & Viee Paul Maff

  28. Slide 28: Financial Information and Market Statistics

    Slide 28: Financial Information and Market Statistics

    Financial Information and Market Statistics Financial Information (In Mi (As of June 43, 2016, unfess indicated otherwise) $ 5.6 Cash and cash equivalents (as of Mar. 31, 2016) $ 1.0 — Monthly burn rate $ 5.0 Debt - Oxford Finance Lic * 8 Common stock outstanding 20.7 Common equivalents - Series D &

  29. Slide 29: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones

    Slide 29: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones

    DIFFERENTIATED CANCER IMMUNOTHERAPY COMPANY WITH MULTIPLE NEAR-TERM MILESTONES ¢# Novel antibody discovery platform producing multiple novel products with significant commercial potential @ I dand yt ‘y develop strategy | ges antibodies as superior targeting agents ° HuMab-5B1 program holds sigaitto

  30. Slide 30: Company Contacts

    Slide 30: Company Contacts

    Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts David Hansen Gregory Hanson President and CEO Chief Financial Officer dhansen@mabv ‘om gtegoryhanson@mabv

Source: SEC EDGAR · 8-K filed Jun 15, 2016

More decks from MabVax Therapeutics Holdings Inc